Literature DB >> 7510915

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome.

E J Small1, P R Carroll.   

Abstract

OBJECTIVE: To evaluate the relationship between antiandrogen withdrawal and change in prostate-specific antigen (PSA) when the antiandrogen in question is other than flutamide.
METHODS: Presented is a case of a patient in whom the antiandrogen casodex was discontinued after clinical progression despite combined androgen blockade.
RESULTS: A transient decline in serum PSA was observed after casodex withdrawal.
CONCLUSIONS: The relationship between antiandrogen withdrawal and a change in PSA may be a general phenomenon, not unique to flutamide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510915     DOI: 10.1016/0090-4295(94)90092-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  33 in total

Review 1.  Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Authors:  Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina
Journal:  Endocr Relat Cancer       Date:  2015-02-26       Impact factor: 5.678

Review 2.  Secondary hormonal manipulations in prostate cancer.

Authors:  Charles J Ryan; Eric J Small
Journal:  Curr Oncol Rep       Date:  2005-05       Impact factor: 5.075

3.  The type of patients who would benefit from anti-androgen withdrawal therapy: could it be performed safely for aggressive prostate cancer?

Authors:  Kazuhiro Matsumoto; Nobuyuki Tanaka; Nozomi Hayakawa; Taisuke Ezaki; Kenjiro Suzuki; Takahiro Maeda; Akiharu Ninomiya; So Nakamura
Journal:  Med Oncol       Date:  2013-06-25       Impact factor: 3.064

Review 4.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

Review 5.  Bicalutamide in advanced prostate cancer. A review.

Authors:  K L Goa; C M Spencer
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

6.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).

Authors:  A Oliver Sartor; Catherine M Tangen; Maha H A Hussain; Mario A Eisenberger; Minoti Parab; Joseph A Fontana; Robert A Chapman; Glenn M Mills; Derek Raghavan; E David Crawford
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

7.  Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.

Authors:  Cheng-Lung Hsu; Jai-Shin Liu; Po-Long Wu; Hong-Hsiang Guan; Yuh-Ling Chen; An-Chi Lin; Huei-Ju Ting; See-Tong Pang; Shauh-Der Yeh; Wen-Lung Ma; Chung-Jung Chen; Wen-Guey Wu; Chawnshang Chang
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

Review 8.  Androgen receptor antagonists in castration-resistant prostate cancer.

Authors:  Dana Rathkopf; Howard I Scher
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

9.  Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines.

Authors:  Makarand V Khochikar
Journal:  Indian J Urol       Date:  2007-01

10.  A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.

Authors:  Yiu-Keung Lau; Manpreet K Chadha; Alan Litwin; Donald L Trump
Journal:  J Hematol Oncol       Date:  2008-11-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.